HC Wainwright Reaffirms “Buy” Rating for Stoke Therapeutics (NASDAQ:STOK)
Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $47.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 464.23% from the stock’s previous close. HC […]
Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $47.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 464.23% from the stock’s previous close. HC […]
